European Union

Adding an IVD specimen matrix? Map extraction, detection and clinical evidence to each configuration, then assess the bridge and regulatory change separately.

Report discordant IVD study results without relabeling the original comparison. See FDA’s recommendations, a synthetic specimen ledger, and separate resolver reporting.

Connect measured biotin interference to U.S. package-insert wording and EU IVDR instructions for use, using FDA’s recommended test range and assay-specific evidence.

Choose a defensible operating altitude for medical electrical equipment, with clearance calculations, thermal evidence, and separate EMS and aircraft assessments.

What to submit to FDA when a supplier won't or can't disclose SBOM component data: the sponsor's 524B duty, the justification route, purchasing controls, and evidence limits.

How RA/QA teams investigate medical device transport damage photos, satisfy QMSR and EU MDR complaint rules, and reconcile field damage against packaging validation.

Learn how to classify medical device pilot builds under FDA QMSR and ISO 13485, separate engineering evidence from saleable product, and handle investigational distribution.

Compare FDA and EU MDR routes for reusable device life: when to claim a fixed reprocessing cycle count versus end-of-life criteria, and what aging evidence regulators accept.

How to build an audit-ready medical device label durability evidence chain against validated cleaning and disinfection cycles rather than generic peel tests.

Support IVD specimen stability claims under 21 CFR 809.10 and EU IVDR Annex II by aligning labeled collection, additives, hold times, and transport with verified study configurations.

How medical device manufacturers structure customer transition plans when software reaches end of support, mapping required evidence, IMDRF milestones, and surviving duties.

How FDA guidance and the EU MDR decide which device models one test report covers, and which records justify an untested size or configuration.

When a laboratory may adopt an IVD manufacturer's reference interval, when CLIA requires verification or establishment, and what ISO 15189 adds only for accredited laboratories.

A practical decision guide to UDI placement across medical device packaging levels under FDA, EU MDR, and TGA rules, covering carriers, unique identifiers, and shipper exemptions.

A manufacturer guide to EU MDR Article 1(8) and 1(9): classify integral ancillary devices, medicinal products, and administration devices with the four-scenario identity worksheet.

A medical device RA/QA guide to records custody when changing distributors: who keeps complaint and traceability files under US, EU, and Canadian post-market rules.

How medical device RA/QA teams reconcile units, ISO symbols, and released versions across translation cycles before artwork issuance under FDA QMSR 820.45 and EU MDR GSPR 23.

When a supplier change notice omits affected lots, dates, or technical details, device QA must hold unverified product, issue an evidence request, and halt close-out until facts are verified.

Evaluate whether a configurable EDC study build can reconstruct device models, firmware versions, deficiencies, and endpoint records for FDA and EU MDR trials.

MDCG 2026-4 EUDAMED SSCP and SSP upload guide: NB interim duties, manufacturer handover in October 2026, Article 32 vs 29(4), and the 27 February 2027 clock.